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Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients 
with non-small cell lung cancer who are refractory or resistant to first-line plati-
num-based chemotherapy. There has been no previous report of bowel perforation 
with or without gastrointestinal metastases related to erlotinib in patients with non-
small cell lung cancer. The exact mechanism of bowel perforation in patients who 
received erlotinib remains unclear. In this report, we report the first case of entero-
cutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 
months, following medication with erlotinib as second-line chemotherapy.  
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INTRODUCTION
Chemotherapy is a mainstay treatment for advanced or metastatic non-small cell 
lung cancer (NSCLC).1 Erlotinib, an epidermal growth factor receptor-tyrosine ki-
nase inhibitor (EGFR-TKI), has been shown to be effective for Asian patients with 
favorable clinical features, such as female gender, never or non-smoker, and ade-
nocarcinoma.2 The most common adverse effect is skin rash. However, other ad-
verse effects are relatively minor and manageable.2-6
Among several targeted agents with different mechanisms of action, patients 
treated with vascular endothelial growth factor (VEGF)-targeted agents, such as be-
vacizumab, develop hypertension, thrombosis, gastrointestinal bleeding, and bowel 
perforation as uncommon adverse effects.7-11 However, there has been no previous 
report of gastrointestinal perforation or fistula related to erlotinib administration.
Here, we report a case of enterocutaneous fistula in a patient with NSCLC after 
the ninth course of erlotinib treatment as a second-line palliative chemotherapy.
CASE REPORT
A 66-year-old female was diagnosed with metastatic non-small cell adenocarcino-
ma of the lung [NSCLC; cT4N0M1 for metastases of the lung to the contralateral Yun-Hong Cheon, et al.
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of bone metastasis was detected in the bone biopsy speci-
men, which was compatible with a benign compression frac-
ture related to severe osteoporosis. Additionally, ibuprofen 
(200 mg three times daily) was added to relieve low back 
pain for 7 days after the procedures.
Nine months after starting second-line chemotherapy with 
erlotinib, the patient was admitted with purulent yellowish 
sputum, cough, and mild shortness of breath without abdom-
inal symptoms. Chest CT scan demonstrated decreased size 
of the primary lung mass, which was still evaluated as a par-
tial response, with focal, patchy consolidation and peribron-
chial thickening in the left lung field, clinically compatible 
with pneumonia. 
On physical examination, a coarse breathing sound with 
a crackle, especially in the left lung field, was detected, and 
an enterocutaneous fistula with leakage of fecal material 
was found in the previous sigmoid colon herniation through 
the abdominal wall defect (Fig. 1A and B). Nevertheless, 
no sign of strangulation, including tenderness or rebound 
tenderness, was observed. Fistulography also demonstrated 
passage of contrast media into the sigmoid colon without 
another fistula (Fig. 2). Further administration of erlotinib 
was withheld after documentation of the enterocutaneous 
fistula. 
After resolution of pneumonia via empirical antibiotic 
treatment for 14 days, a scheduled sigmoid colon resection 
and primary anastomosis were performed at the Depart-
ment of General Surgery. Surgical pathologic findings in-
cluded submucosal edema and serosal hemorrhage of the 
perforated sigmoid colon, consistent with enterocutaneous 
fistula and no metastatic tumor foci in the sigmoid colon 
(Fig. 3A and B). Ten days postoperatively, the patient was 
discharged with complete recovery from the enterocutane-
ous fistula. She was alive and well on regular follow-up at 
lung and pleura on 18F-fluorodeoxyglucose positron emis-
sion tomography computed tomography (FDG-PET CT) 
scan] in January 2008. The patient had a history of explor-
atory laparotomy and a total hysterectomy, due to acute ab-
domen about 30 years earlier. Physical examination re-
vealed sigmoid colon herniation through an abdominal wall 
defect, with no sign or symptom of strangulation. Although 
surgical management of the herniated colon loop and clo-
sure of the abdominal wall were strongly recommended, 
she refused further surgical treatment, because there had 
been no symptom, such as abdominal pain or bowel habit 
abnormality associated with the sigmoid colon herniation, 
over the previous 30 years.
She was treated with a first-line chemotherapy, including 
cisplatin (70 mg/m2, day 1) and docetaxel (70 mg/m2, day 
1) every 3 weeks for 6 cycles from January 2008 to July 
2008. Following completion of 6 cycles of first-line chemo-
therapy, a chest CT scan showed a partial response, accord-
ing to the Response Evaluation Criteria in Solid Tumors 
(RECIST).
In October 2008, second-line chemotherapy with erlo-
tinib was started because a follow-up chest CT scan re-
vealed regrowth of the primary lung mass in the left upper 
lobe and increased malignant pleural effusion. A subse-
quent chest CT scan showed persistent partial response at 
the first, third, fifth, and seventh month following erlotinib 
administration.
In November 2008 (seventh month following erlotinib 
administration), the patient complained of low back pain 
after a fall at home, and a compression fracture of the fifth 
lumbar vertebra was detected on a simple spine X-ray and 
spine magnetic resonance image (MRI). Percutaneous ver-
tebroplasty and concomitant bone biopsy were performed 
at the Department of Neurosurgery. However, no evidence 
Fig. 2. Fistulography shows well passage of contrast media into the sigmoid 
colon without another fistu.
Fig. 1. (A and B) White arrow indicates an enterocutaneous fistula in the 
sigmoid colon herniation through the abdominal wall defect.
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to bowel perforation regardless of their mechanism of ac-
tion, especially in patients with visceral metastases caused 
by tumor regression and necrosis, our patient showed no ev-
idence of bowel metastasis, according to radiologic findings 
at initial diagnosis or during administration of erlotinib, or 
pathologic findings of the post-operative resected bowel 
specimen.
In conclusion, physicians should be aware of the rare, but 
possible, adverse effect of bowel perforation or fistula fol-
lowing administration of erlotinib, even in NSCLC patients 
without visceral metastases, and erlotinib administration 
should be discontinued when patients develop gastrointesti-
nal perforation.
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